비혈관용 스텐트 시장 : 제품 유형, 재질, 피복 구조, 회수성, 제조 방법, 적응증, 용도, 최종사용자별 - 세계 예측(2026-2032년)

The Non-vascular Stents Market is projected to grow by USD 2.91 billion at a CAGR of 6.13% by 2032.

Non-vascular stents are critical implantable devices used to restore or preserve lumen patency outside the vascular system, including the biliary tract, gastrointestinal tract, airway, ureter, pancreas, prostate, and esophagus. Demand is supported by the documented clinical burden of cancer, benign strictures, stone disease, chronic obstructive pulmonary disease, and age-related obstruction, all of which are recognized priorities across WHO, GLOBOCAN, OECD, and national health system datasets.

The non-vascular stents market is moving from purely mechanical palliation toward procedure-enabling, image-guided, and increasingly customized solutions. Self-expanding metal stents, covered stents, polymeric devices, anti-migration designs, and biodegradable platforms are reshaping care pathways by reducing repeat interventions and supporting less invasive treatment across endoscopy, interventional pulmonology, and urology.

Transformative Shifts in the Non-Vascular Stents Landscape

The non-vascular stents landscape is being transformed by three structural forces: minimally invasive care, material innovation, and tighter evidence expectations. Hospitals are prioritizing endoscopic and image-guided procedures that can shorten length of stay and reduce open surgical risk, while device developers are improving radial force, conformability, migration resistance, removability, and drug compatibility.

Clinical practice is also shifting toward indication-specific devices rather than one-size-fits-all stents. Biliary stents are benefiting from advances in covered metal designs, airway stents from silicone and hybrid configurations, and urological stents from coatings designed to reduce encrustation and infection risk. Regulatory agencies are simultaneously emphasizing clinical performance, biocompatibility, post-market surveillance, and real-world evidence, making data quality a core competitive advantage.

Cumulative Impact of Artificial Intelligence

Artificial intelligence is creating cumulative value across the non-vascular stents ecosystem, beginning with diagnosis and case selection. AI-enabled imaging workflows can support the detection of strictures, obstruction, tumor burden, stone-related complications, and airway narrowing, helping clinicians plan device size, placement route, and follow-up protocols with greater consistency.

AI is also influencing product development and operations. Machine learning can accelerate finite element modeling, fatigue testing simulations, coating optimization, adverse event signal detection, inventory planning, and physician training analytics. While AI does not replace clinical judgment, its integration into imaging, navigation, manufacturing quality systems, and real-world data analysis is expected to improve procedural planning and reduce avoidable variation in stent performance.

Key Regional Insights

Asia-Pacific is expanding as China, India, Japan, South Korea, and Australia invest in endoscopy capacity, oncology care, and minimally invasive urology. Large patient pools, rising cancer diagnosis, gallstone disease, and broader insurance coverage are increasing demand for biliary, esophageal, ureteral, and airway stents, while local manufacturing strengthens price competition and availability.

North America remains a high-value region due to advanced hospital infrastructure, strong adoption of interventional endoscopy and pulmonology, and established FDA and Health Canada pathways for device safety and surveillance. Europe benefits from mature reimbursement systems, specialist centers, and EU Medical Device Regulation requirements that raise evidence standards. Latin America shows improving adoption through private hospital networks and oncology access improvements, led by Brazil and Mexico. The Middle East is supported by tertiary care investments, particularly across GCC countries, while Africa remains an access-led opportunity where specialist availability, procurement funding, referral infrastructure, and training capacity shape adoption.

Key Group Insights

ASEAN demand is being driven by healthcare infrastructure upgrades in Singapore, Malaysia, Thailand, Indonesia, Vietnam, and the Philippines, with endoscopy and urology access improving unevenly across public and private systems. The GCC is characterized by premium tertiary hospitals, high medical technology adoption, and centralized procurement, especially in Saudi Arabia and the United Arab Emirates, where oncology, gastroenterology, and urology services are expanding.

The European Union offers a large regulated environment where MDR compliance, clinical evidence, traceability, and notified body capacity influence launch timelines and product continuity. BRICS countries combine large disease burden with expanding local manufacturing and cost-sensitive procurement, making value-based product positioning essential. G7 markets remain innovation-led and reimbursement-sensitive, with strong emphasis on clinical outcomes and post-market evidence, while NATO countries overlap with many advanced healthcare systems that emphasize supply chain resilience, cybersecurity, and continuity of medical device availability.

Key Country Insights

The United States leads in premium non-vascular stent adoption because of advanced procedural capacity, strong specialty society guidance, and established reimbursement for endoscopic, pulmonary, and urologic interventions. Canada emphasizes evidence-based access across provincial systems, while Mexico and Brazil are expanding demand through private hospitals, urban specialty centers, and improving oncology and gastroenterology services.

In Europe, the United Kingdom, Germany, France, Italy, and Spain combine aging populations with established endoscopy networks, though MDR compliance, health technology assessment expectations, and hospital budget controls affect purchasing cycles. Russia remains influenced by localization and public procurement policy. In Asia-Pacific, China and India are scale markets with rising cancer, gastrointestinal disease, and urological obstruction management needs; Japan and South Korea are innovation-focused with sophisticated clinical practice and advanced endoscopic capability; and Australia maintains high standards for device evaluation, specialist access, and clinical governance.

Actionable Recommendations for Industry Leaders

Industry leaders should prioritize evidence generation, differentiated design, and reliable supply. Clinical data demonstrating lower migration, reduced reintervention, improved patency, and safe removability can strengthen market access discussions with hospitals, payers, and regulators.

Manufacturers should invest in indication-specific portfolios, AI-supported design validation, coating technologies, physician education, and post-market surveillance. Commercial teams should align products with regional reimbursement realities, expand training in emerging markets, and build resilient sourcing strategies for nitinol, silicone, polymers, delivery systems, and sterilization capacity.

Research Methodology

This executive summary is based on secondary research from public health agencies, regulatory guidance, peer-reviewed clinical literature, hospital technology trends, and public disclosures related to non-vascular stents. Sources considered include WHO, GLOBOCAN, FDA, European Commission MDR materials, OECD health indicators, national health statistics, and specialty society publications in gastroenterology, pulmonology, and urology.

The analysis applies triangulation across disease burden, procedure adoption, reimbursement trends, regulatory requirements, product innovation, and regional healthcare infrastructure. Insights are synthesized qualitatively to support strategic decision-making without relying on unverified market sizing, market share, or forecasting claims.

Conclusion

The non-vascular stents market is positioned for continued relevance as healthcare systems expand minimally invasive treatment for malignant and benign obstruction. Clinical demand is broad, spanning gastroenterology, urology, pulmonology, and oncology, while product competition increasingly depends on performance evidence and procedure-specific design.

Organizations that combine strong clinical validation, AI-enabled development, regional market access discipline, and dependable manufacturing will be best positioned to address demand across mature and emerging healthcare systems. The next phase of competition will favor devices that improve patency, reduce complications, and support efficient care delivery.

Table of Contents

1. Preface

• 1.1. Objectives of the Study
• 1.2. Market Definition
• 1.3. Market Segmentation & Coverage
• 1.4. Years Considered for the Study
• 1.5. Currency Considered for the Study
• 1.6. Language Considered for the Study
• 1.7. Key Stakeholders

2. Research Methodology

• 2.1. Introduction
• 2.2. Research Design
  • 2.2.1. Primary Research
  • 2.2.2. Secondary Research
• 2.3. Research Framework
  • 2.3.1. Qualitative Analysis
  • 2.3.2. Quantitative Analysis
• 2.4. Market Size Estimation
  • 2.4.1. Top-Down Approach
  • 2.4.2. Bottom-Up Approach
• 2.5. Data Triangulation
• 2.6. Research Outcomes
• 2.7. Research Assumptions
• 2.8. Research Limitations

3. Executive Summary

• 3.1. Introduction
• 3.2. CXO Perspective
• 3.3. Market Size & Growth Trends
• 3.4. Market Share Analysis, 2025
• 3.5. FPNV Positioning Matrix, 2025
• 3.6. New Revenue Opportunities
• 3.7. Next-Generation Business Models
• 3.8. Industry Roadmap

4. Market Overview

• 4.1. Introduction
• 4.2. Industry Ecosystem & Value Chain Analysis
  • 4.2.1. Supply-Side Analysis
  • 4.2.2. Demand-Side Analysis
  • 4.2.3. Stakeholder Analysis
• 4.3. Market Dynamics
  • 4.3.1. Key Drivers
  • 4.3.2. Key Restraints
  • 4.3.3. Key Opportunities
  • 4.3.4. Key Challenges
• 4.4. Porter's Five Forces Analysis
• 4.5. PESTLE Analysis
• 4.6. Market Outlook
  • 4.6.1. Near-Term Market Outlook (0-2 Years)
  • 4.6.2. Medium-Term Market Outlook (3-5 Years)
  • 4.6.3. Long-Term Market Outlook (5-10 Years)
• 4.7. Go-to-Market Strategy

5. Market Insights

• 5.1. Consumer Insights & End-User Perspective
• 5.2. Consumer Experience Benchmarking
• 5.3. Opportunity Mapping
• 5.4. Distribution Channel Analysis
• 5.5. Pricing Trend Analysis
• 5.6. Regulatory Compliance & Standards Framework
• 5.7. ESG & Sustainability Analysis
• 5.8. Disruption & Risk Scenarios
• 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of Artificial Intelligence 2026

7. Non-vascular Stents Market, by Product Type

• 7.1. Balloon-Expandable
• 7.2. Self-Expanding

8. Non-vascular Stents Market, by Material Type

• 8.1. Nitinol
• 8.2. Polymeric
• 8.3. Stainless Steel

9. Non-vascular Stents Market, by Coverage Configuration

• 9.1. Covered
• 9.2. Partially Covered
• 9.3. Uncovered

10. Non-vascular Stents Market, by Retrievability

• 10.1. Retrievable
• 10.2. Non-Retrievable

11. Non-vascular Stents Market, by Construction Method

• 11.1. Braided
• 11.2. Laser-Cut
• 11.3. Woven

12. Non-vascular Stents Market, by Clinical Indication

• 12.1. Benign Strictures
• 12.2. Malignant Obstruction
• 12.3. Leaks And Fistulas

13. Non-vascular Stents Market, by Application

• 13.1. Airway
  • 13.1.1. Bronchial
  • 13.1.2. Tracheal
• 13.2. Biliary
• 13.3. Gastrointestinal
  • 13.3.1. Colorectal
  • 13.3.2. Duodenal
  • 13.3.3. Esophageal
• 13.4. Urological
  • 13.4.1. Prostatic
  • 13.4.2. Ureteral
  • 13.4.3. Urethral

14. Non-vascular Stents Market, by End User

• 14.1. Ambulatory Surgical Center
• 14.2. Hospitals

15. Non-vascular Stents Market, by Region

• 15.1. Asia-Pacific
• 15.2. North America
• 15.3. Latin America
• 15.4. Europe
• 15.5. Middle East
• 15.6. Africa

16. Non-vascular Stents Market, by Group

• 16.1. ASEAN
• 16.2. GCC
• 16.3. European Union
• 16.4. BRICS
• 16.5. G7
• 16.6. NATO

17. Non-vascular Stents Market, by Country

• 17.1. United States
• 17.2. Canada
• 17.3. Mexico
• 17.4. Brazil
• 17.5. United Kingdom
• 17.6. Germany
• 17.7. France
• 17.8. Russia
• 17.9. Italy
• 17.10. Spain
• 17.11. China
• 17.12. India
• 17.13. Japan
• 17.14. Australia
• 17.15. South Korea

18. Competitive Landscape

• 18.1. Market Concentration Analysis, 2025
  • 18.1.1. Concentration Ratio (CR)
  • 18.1.2. Herfindahl Hirschman Index (HHI)
• 18.2. Recent Developments & Impact Analysis, 2025
• 18.3. Product Portfolio Analysis, 2025
• 18.4. Benchmarking Analysis, 2025

19. Company Profiles

• 19.1. Abbott Laboratories
• 19.2. Allium Medical Solutions Ltd.
• 19.3. B. Braun Melsungen AG
• 19.4. Becton, Dickinson and Company
• 19.5. Boston Scientific Corporation
• 19.6. Changzhou Health Microport Medical Device Co., Ltd.
• 19.7. Coloplast A/S
• 19.8. CONMED Corporation
• 19.9. Cook Medical LLC
• 19.10. ELLA-CS, s.r.o.
• 19.11. Endo GI Medical Ltd.
• 19.12. Endo-Flex GmbH
• 19.13. Fujifilm Holdings Corporation
• 19.14. Glaukos Corporation
• 19.15. Hobbs Medical, Inc.
• 19.16. Hoya Corporation
• 19.17. M.I.Tech Co., Ltd.
• 19.18. Medi-Globe GmbH
• 19.19. Medtronic plc
• 19.20. Merit Medical Systems, Inc.
• 19.21. Micro-Tech (Nanjing) Co., Ltd.
• 19.22. Olympus Corporation
• 19.23. Optimed Medizinische Instrumente GmbH
• 19.24. Pentax Medical
• 19.25. S.B. Kawasumi Laboratories, Inc.
• 19.26. Stening SRL
• 19.27. Taewoong Medical Co., Ltd.
• 19.28. Teleflex Incorporated
• 19.29. Terumo Corporation
• 19.30. W. L. Gore & Associates, Inc.